Clinical trial
Alefacept Mechanism of Action in Psoriasis
NCT00150982 · University of Medicine and Dentistry of New Jersey, Other · Completed
Key facts
| NCT number | NCT00150982 |
|---|---|
| Title | Alefacept Mechanism of Action in Psoriasis |
| Official title | In Vivo Induction of T Cell Apoptosis by Alefacept (LFA-3/IgG1 Fusion Protein, Amevive) in Patients With Psoriasis: An Investigator-Initiated, Open-Label, Mechanism of Action Study |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Mechanism of action of alefacept |
| Enrollment | 9 |
| Start date | Sep 1, 2003 |
| Completion | Feb 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Aug 7, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: